| | Forest Laboratories Licensing Frequently Asked Questions |
 | | A: Our collaborations have delivered a number of important drugs to market including: Lexapro®(escitalopram oxalate), a widely prescribed antidepressant; Namenda®(memantine HCl), the first drug approved for the treatment of moderate and severe Alzheimer’s disease; and Campral® (acamprosate calcium), the first new drug approved for alcohol dependency in a decade. |
 | | Our sales forces—which reach primary care physicians, psychiatrists, neurologists, hospitals, managed care organizations and senior care providers nationwide – have a track record of helping to establish drugs like Lexapro®(escitalopram oxalate) and Namenda®(memantine HCl) as leaders in their categories. |
 | | The launches of Celexa®(citalopram HBr), Lexapro®(escitalopram oxalate), Benicar®(olmesartan medoxomil) and Namenda®(memantine HCl) have all been cited by pharmaceutical industry observers as being among the most successful new product introductions in their respective years. |
| www.frx.com /licensing/faqs.aspx (985 words) |